Suppr超能文献

分析人类临床肿瘤样本中的蛋白质生物标志物:从组织采集到分析成功的关键方面。

Analysis of protein biomarkers in human clinical tumor samples: critical aspects to success from tissue acquisition to analysis.

机构信息

Pathology Diagnostics Ltd, St John's Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK.

出版信息

Biomark Med. 2011 Apr;5(2):227-48. doi: 10.2217/bmm.11.9.

Abstract

There has been increased interest in the analysis of protein biomarkers in clinical tumor tissues in recent years. Tissue-based biomarker assays can add value and aid decision-making at all stages of drug development, as well as being developed for use as predictive biomarkers and for patient stratification and prognostication in the clinic. However, there must be an awareness of the legal and ethical issues related to the sourcing of human tissue samples. This article also discusses the limits of scope and critical aspects on the successful use of the following tissue-based methods: immunohistochemistry, tissue microarrays and automated image analysis. Future advances in standardization of tissue biobanking methods, immunohistochemistry and quantitative image analysis techniques are also discussed.

摘要

近年来,人们对分析临床肿瘤组织中的蛋白质生物标志物越来越感兴趣。基于组织的生物标志物检测可以在药物开发的各个阶段增加价值并辅助决策,并且还可以作为预测生物标志物以及在临床中进行患者分层和预后预测而开发。但是,必须意识到与人类组织样本来源相关的法律和道德问题。本文还讨论了以下基于组织的方法的成功使用的范围限制和关键方面:免疫组织化学、组织微阵列和自动图像分析。还讨论了组织生物库方法、免疫组织化学和定量图像分析技术的标准化的未来进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验